These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7787254)

  • 1. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
    Kaplan JB
    Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
    Yokoyama T
    Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism.
    Delgado MD; Vaqué JP; Arozarena I; López-Ilasaca MA; Martínez C; Crespo P; León J
    Oncogene; 2000 Feb; 19(6):783-90. PubMed ID: 10698496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
    Saez R; Chan AM; Miki T; Aaronson SA
    Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor.
    Chen SY; Huff SY; Lai CC; Der CJ; Powers S
    Oncogene; 1994 Sep; 9(9):2691-8. PubMed ID: 8058333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel human ERK phosphatase regulates H-ras and v-raf signal transduction.
    Shin DY; Ishibashi T; Choi TS; Chung E; Chung IY; Aaronson SA; Bottaro DP
    Oncogene; 1997 Jun; 14(22):2633-9. PubMed ID: 9178761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for Ras in v-Crk transformation.
    Greulich H; Hanafusa H
    Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
    Xin H; Geng Y; Pramanik R; Choubey D
    J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. trans-Dominant suppressor mutations of the H-ras oncogene.
    Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
    Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
    Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
    Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras- and Raf-mediated regulation of transforming growth factor beta 1 gene expression by ligands of tyrosine kinase receptors in PC12 cells.
    Cosgaya JM; Aranda A
    Oncogene; 1996 Jun; 12(12):2651-60. PubMed ID: 8700524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
    Shantz LM; Pegg AE
    Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
    Rapp UR; Troppmair J; Beck T; Birrer MJ
    Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of myeloid cell growth by distinct effectors of Ras.
    Matsuguchi T; Kraft AS
    Oncogene; 1998 Nov; 17(21):2701-9. PubMed ID: 9840934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator.
    Okazaki M; Kishida S; Hinoi T; Hasegawa T; Tamada M; Kataoka T; Kikuchi A
    Oncogene; 1997 Feb; 14(5):515-21. PubMed ID: 9053849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40.
    Raptis L; Brownell HL; Corbley MJ; Wood KW; Wang D; Haliotis T
    Cell Growth Differ; 1997 Aug; 8(8):891-901. PubMed ID: 9269898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
    Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
    Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.